Clinical trial
Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive…
NCT00383097 · Baylor College of Medicine, Other · Terminated
Key facts
| NCT number | NCT00383097 |
|---|---|
| Title | Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma |
| Official title | Administration of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes Following CD45 Antibody to Patients With Relapsed EBV-Positive Hodgkin's or Non-Hodgkin's Lymphoma or Chronic Active EBV Infection (ALDI) |
| Acronym | ALDI |
| Lead sponsor | Baylor College of Medicine, Other |
| Collaborators | The Methodist Hospital Research Institute |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hodgkins Lymphoma, Non-Hodgkin Lymphoma |
| Intervention type | Genetic |
| Interventions | LMP1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES, LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES |
| Enrollment | 6 |
| Start date | Sep 1, 2006 |
| Primary completion | Feb 1, 2010 |
| Completion | Feb 1, 2010 |
| First posted | Oct 2, 2006 |
| Last update posted | May 24, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: